IQVIA Recognized as a Leader in IDC MarketScape’s 2024 Assessment for Decentralized Clinical Trial Technologies and Consulting Services
IQVIA, a global leader in AI-powered analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, has been named to the “Leaders” category in the IDC MarketScape: Worldwide Life Science R&D Decentralized Clinical Trial Technology Solutions and Consulting Services 2024 Vendor Assessment. This recognition underscores IQVIA’s expertise and leadership in the rapidly growing field of decentralized clinical trials (DCTs), which are transforming how clinical research is conducted.
IDC MarketScape’s Evaluation Criteria
IDC, a trusted global provider of market intelligence, highlighted IQVIA’s strong position in the DCT sector. The IDC MarketScape report noted that IQVIA offers a comprehensive set of capabilities, including over 200 DCT consultants, a broad portfolio of DCT-enabling technologies, and expertise in regulatory strategy for implementing DCT models across various countries. Furthermore, IQVIA’s approach to integrating healthcare-grade AI, including novel GenAI tools, positions it at the forefront of improving the patient experience and operational efficiency in clinical trials.
The report elaborates on IQVIA’s ability to deliver value across therapeutic areas and clinical trial phases, emphasizing its strength in providing strategic guidance for DCT implementation and business process transformation. IDC’s analysis also underscores IQVIA’s ability to help life sciences companies adapt to the evolving needs of decentralized trials, focusing on delivering end-to-end solutions that enhance trial success.
The Growing Importance of Decentralized Clinical Trials
Decentralized clinical trials (DCTs) have rapidly evolved, particularly during the COVID-19 pandemic, when traditional in-person trials faced significant challenges. DCTs leverage telemedicine, wearable devices, mobile technologies, and digital tools to monitor patients remotely, enabling clinical trial activities to take place outside of conventional clinical sites. As a result, patients can participate in trials from their homes, with fewer visits required to physical sites. This model not only improves patient convenience but also enhances the reach of clinical trials, allowing for more diverse and inclusive participant pools.
Dr. Nimita Limaye, IDC’s research vice president for Life Sciences R&D Strategy and Technology, observed that DCTs are becoming an integral part of the clinical trial landscape. “Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay,” Dr. Limaye wrote. “The focus is on integration: integrating technologies, integrating touchpoints to create unified and meaningful experiences, and aligning technologies with operating models. The industry’s view of DCTs is maturing. DCTs aren’t going away. They’re becoming a ‘business as usual’ strategy today.”
IQVIA’s Integrated Strategy for Decentralized Trials
IQVIA’s success in the decentralized clinical trial space is driven by its integrated strategy, which focuses on helping clients adopt, implement, and execute DCT approaches. By leveraging its advanced technologies and consulting expertise, IQVIA offers a unique experience that sets it apart in the marketplace.
At the heart of IQVIA’s approach is its ability to offer a full suite of solutions that enhance both patient and site experiences. This integrated model ensures that decentralized trials are executed efficiently and effectively, providing the necessary tools and support for seamless collaboration across all stakeholders.
Susan Hill, senior vice president of product management for Digital Products & Solutions at IQVIA, expressed pride in the company’s leadership position. “At IQVIA, we are proud to be a leader in decentralized clinical trials and remain focused on delivering cutting-edge technology solutions that enhance patient and site experiences and drive healthcare forward,” Hill stated.
Alison Liddy, senior vice president for Patient and Site Centric Solutions at IQVIA, emphasized the significance of this recognition. “Being named a Leader in the IDC MarketScape report highlights our commitment to revolutionizing clinical trials through innovation and excellence,” Liddy said. “We are honored to receive this distinction and empower our customers to achieve outstanding results.”
IDC’s First Comprehensive Assessment of DCT Solutions and Consulting
The IDC MarketScape report represents the first comprehensive assessment of both DCT technology solutions and consulting services in life science R&D. In its evaluation, IDC analyzed vendors based on their capabilities, strategies, and market success factors, ultimately recognizing IQVIA for its leadership in this rapidly evolving space.
IQVIA’s comprehensive approach to DCT solutions, which includes a combination of advanced technology platforms, consulting services, and regulatory expertise, positions it as a trusted partner for life sciences companies looking to implement decentralized trials. With over 200 DCT consultants on its team, IQVIA is well-equipped to guide clients through the complexities of decentralized trial design, implementation, and optimization.
The Future of Decentralized Clinical Trials
As decentralized clinical trials continue to gain traction, IQVIA’s leadership in this area is poised to shape the future of clinical research. The shift toward decentralized trials is expected to accelerate as technology evolves and as more stakeholders recognize the advantages of flexible, patient-centric trial models.
IQVIA’s focus on integrating advanced AI technologies, including generative AI (GenAI), further enhances its ability to transform the patient experience, streamline trial operations, and improve data collection. These innovations are helping to set new standards for decentralized clinical trials, providing a more efficient and effective way to conduct research while expanding access for patients.
The recognition in the IDC MarketScape report underscores IQVIA’s continued dedication to driving innovation in clinical trials and its role as a leader in the life sciences industry. As decentralized trials become a mainstream approach, IQVIA is well-positioned to support life sciences companies in navigating the complexities of this new model, ultimately advancing healthcare and improving patient outcomes.
Read the 2024 IDC MarketScape excerpt here.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
